Related Experiment Video
Updated: Jun 24, 2026
08:28
Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
Published on: April 5, 2011
A case of flecainide-induced hyponatremia
Mubashir Ahmed1, Jasbir Sra, Masood Akhtar
1Electrophysiology Laboratories of Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health-Milwaukee Clinical Campus, Milwaukee, Wisconsin, USA.
Journal of Cardiovascular Electrophysiology
|March 21, 2009
Summary
Flecainide, a medication for atrial tachycardia, can cause hyponatremia (low sodium levels). This case highlights a previously unrecognized adverse effect of flecainide, emphasizing the need for monitoring sodium levels in patients taking this drug.
Area of Science:
- Cardiology
- Clinical Pharmacology
- Nephrology
Background:
- Flecainide is a Class Ic antiarrhythmic agent commonly prescribed for supraventricular tachycardias.
- Hyponatremia, a potentially serious electrolyte imbalance, can arise from various causes, including medication side effects.
Observation:
- A 67-year-old woman developed dizziness and was diagnosed with severe hyponatremia (serum sodium 122 mmol/L) shortly after initiating flecainide therapy for paroxysmal atrial tachycardia.
- Comprehensive investigations excluded other common etiologies for hyponatremia, such as diuretic use, laxative abuse, or herbal supplement interactions.
Findings:
- Discontinuation of flecainide led to a significant improvement in the patient's clinical symptoms and normalization of serum sodium levels.
- This case suggests a direct causal link between flecainide administration and the development of hyponatremia, representing a novel adverse drug reaction.
Implications:
- Clinicians should consider flecainide-induced hyponatremia as a potential diagnosis in patients presenting with unexplained low sodium levels, particularly those on this antiarrhythmic medication.
- Further research is warranted to elucidate the precise mechanism underlying flecainide-associated hyponatremia and to establish monitoring guidelines.
Related Concept Videos
00:42Ionic Bonds
When atoms gain or lose electrons to achieve a more stable electron configuration they form ions. Ionic bonds are electrostatic attractions between ions with opposite charges. Ionic compounds are rigid and brittle when solid and may dissociate into their constituent ions in water. Covalent compounds, by contrast, remain intact unless a chemical reaction breaks them.Opposing Charges Hold Ions Together in Ionic CompoundsIonic bonds are reversible electrostatic interactions between ions with...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...